The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
about
Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?Metformin and the gastrointestinal tractThe dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patientsIncretin response in Asian type 2 diabetes: Are Indians different?Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian SubjectsDiabetes impairs stem cell and proangiogenic cell mobilization in humans.Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus.Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathwayEfficacy and safety of Jentadueto® (linagliptin plus metformin).Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice.Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy
P2860
Q26744254-C8279365-9142-4381-A3BA-9E76222505CFQ27006992-CC2D1495-CA05-47CA-93CE-4E13D94DFE4FQ28079250-51C704BD-CF24-406F-BC84-5E837DE60BC1Q33662677-EAAB646A-D691-46C2-9A54-B34FB5C1E5CDQ34878323-B2EF3C35-C4DB-4AE5-BD29-BE084D485FBFQ36170755-78A5AF06-CDFD-4DF9-9D12-C480C2176922Q36720330-C1093366-BF53-4375-99C2-6445B6259540Q37106470-9DF8FA2A-8ED2-488D-B744-9F78448107BAQ37366826-33342C15-AFFF-4CC3-BB01-846E87BAD4B6Q37618348-D875507C-2D3A-4AE3-9851-71D99D0B031CQ38082848-750335EB-D17B-4C87-866A-7AA8A0BD72DEQ38106411-5BFFAF3F-3E59-4DEF-BCBC-D5C6DD1674D8Q38264456-09D517D8-A0AD-480F-923D-52A3725B9DF1Q38410742-B5108FC5-DD6E-45A9-8779-C725BD1E4E03Q38773675-D803C908-89E7-4BC7-9984-A93B442EA03BQ41686499-266BC94A-21E6-47B0-8A4C-700835A71CE0Q58816057-DA897A74-50E5-41D0-85EB-AA6D885AA52B
P2860
The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
The increased dipeptidyl pepti ...... in metformin-treated patients.
@en
The increased dipeptidyl pepti ...... in metformin-treated patients.
@nl
type
label
The increased dipeptidyl pepti ...... in metformin-treated patients.
@en
The increased dipeptidyl pepti ...... in metformin-treated patients.
@nl
prefLabel
The increased dipeptidyl pepti ...... in metformin-treated patients.
@en
The increased dipeptidyl pepti ...... in metformin-treated patients.
@nl
P2093
P2860
P1476
The increased dipeptidyl pepti ...... in metformin-treated patients.
@en
P2093
L Menegazzo
S V de Kreutzenberg
P2860
P304
P356
10.1111/J.1463-1326.2011.01550.X
P577
2012-01-06T00:00:00Z